Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6

References

• Boss J, Welslau U, Ritter J, Blaschke G, Schellong G. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolite in children. Cancer Chemotherapy and Pharmacology 1991; 28: 455–460
   PubMed Web of Science ®Google Scholar
• Brade MP, Herdrich K, Varini M. Ifosfamide — pharmacology, safety and therapeutic potential. Cancer Treatment Reviews 1985; 12: 1–47
   PubMed Web of Science ®Google Scholar
• Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research 1993; 53: 5629–5637
   PubMed Web of Science ®Google Scholar
• Chen CS, Jounaidi Y, Waxman DJ. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochrome P450. Drug Metabolism and Disposition 2005; 33: 1261–1267
   PubMed Web of Science ®Google Scholar
• Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Waxman DJ. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: Identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Molecular Pharmacology 2004; 65: 1278–1285
   PubMed Web of Science ®Google Scholar
• Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TH, Waxman DJ. Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Molecular Pharmacology 1997; 25: 985–993
   Google Scholar
• Doehmer J. V79 Chinese hamster cells genetically engineered for cytochrome P450 and their use in mutagenicity and metabolism studies. Toxicology 1993; 82: 105–118
   PubMed Web of Science ®Google Scholar
• Farmer PB. Enantiomers of cyclophosphamide and iphosphamide. Biochemistry and Pharmacology 1988; 37: 145–148
   PubMed Web of Science ®Google Scholar
• Granvil CP, Ducharme J, Jones BL, Trudeau M, Wainer IW. Enantioselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemotherapy and Pharmacology 1996; 37: 451–456
   PubMed Web of Science ®Google Scholar
• Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metabolism and Disposition 1999; 27: 533–541
   PubMed Web of Science ®Google Scholar
• Granvil CP, Wang T, Batist G, Wainer IW. Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat. Drug Metabolism and Disposition 1994; 22: 165–167
   PubMed Web of Science ®Google Scholar
• Guo Z, Raeissi S, White R, Stevens JC. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metabolism and Disposition 1997; 25: 390–393
   PubMed Web of Science ®Google Scholar
• Kumar S, Chen CS, Waxman DJ, Halpert JR. Directed evolution of mammalian cytochrome P450 2B1. Journal of Biological Chemistry 2005; 280: 19569–19575
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Lu H, Wang JJ, Chan KK, Young D. Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. Drug Metabolism and Disposition 1998; 26: 476–482
   PubMed Web of Science ®Google Scholar
• McCune JS, Risler LJ, Phillips BR, Thummel KE, Blough D, Shen DD. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metabolism and Disposition 2005; 33: 1074–1081
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 1995; 23: 154–158
   PubMed Web of Science ®Google Scholar
• Pessayre D, Konstantinova-Mitcheva M, Descatoire V, Cobert B, Wandscheer JC, Level R, Feldmann G, Mansuy D, Benhamou JP. Hypoactivity of cytochrome P450 after triacetyloleandomycin administration. Biochemistry and Pharmacology 1981; 30: 559–564
   PubMed Web of Science ®Google Scholar
• Philip PA, Ali-Sadat S, Doehmer J, Kocarek T, Akhtar A, Lu H, Chan KK. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs. Cancer Chemotherapy and Pharmacology 1999; 43: 59–67
   PubMed Web of Science ®Google Scholar
• Reidy GF, Mehta I, Murray M. Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Molecular Pharmacology 1989; 35: 736–743
   PubMed Web of Science ®Google Scholar
• Roy P, Tretyakov O, Wright J, Waxman DJ. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6 — favorable metabolic properties of R-enantiomer. Drug Metabolism and Disposition 1999; 27: 1309–1318
   PubMed Web of Science ®Google Scholar
• Soucek P, Gut I. Cytochrome P-450 in rats: Structures, functions, properties and relevant human forms. Xenobiotica 1992; 22: 83–103
   PubMed Web of Science ®Google Scholar
• Speirs CJ, Murray S, Boobis AR, Seddon CE, Davis DS. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. British Journal of Clinical Pharmacology 1986; 22: 739–743
   PubMed Web of Science ®Google Scholar
• Wainer IW, Granvil CP, Wang T, Batist G. Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. Cancer Research 1994a; 54: 4393–4397
   PubMed Web of Science ®Google Scholar
• Wainer IW, Ducharme J, Granvil CP, Trudean M, Leyland-Jones B. Ifosfamide stereoselective dichloroethylation and neurotoxicity. Lancet 1994b; 343: 982–983
   PubMed Web of Science ®Google Scholar
• Wainer IW, Ducharme J, Granvil CP. The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemotherapy and Pharmacology 1996; 37: 332–336
   PubMed Web of Science ®Google Scholar
• Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochemistry and Pharmacology 1994; 47: 1157–1163
   PubMed Web of Science ®Google Scholar
• Wang JH, Chan KK. Identification of new metabolites of ifosfamide in rat urine using ion cluster technique. Journal of Mass Spectrometry 1995a; 30: 675–683
   Web of Science ®Google Scholar
• Wang JH, Chan KK. Analysis of ifosfamide, 4-hydroxyifosfamide, N2-dechloroethylifosfamide, N3-dechloroethylifosfamide, and iphosphoramide mustard in plasma by gas chromatographic-mass spectrometry. Journal of Chromatography B 1995b; 674: 205–217
   PubMed Web of Science ®Google Scholar
• Wang JH, Chan KK. Stereospecific synthesis of tretradeuterated (R)- and (S)-ifosfamide. Journal of Labelled Compounds 1996; 38: 105–115
   Web of Science ®Google Scholar
• Wang JJ, Lu H, Chan KK. Stereoselective pharmacokinetics of ifosfamide in male and female rats. AAPS Pharmscience 2000; 2: 1–11
   Google Scholar
• Weber GF, Waxman DJ. Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochemistry and Pharmacology 1993; 45: 1685–1694
   PubMed Web of Science ®Google Scholar
• Yu L, Waxman DJ. Role of cytochrome P450 in oxazaphosphorine metabolism, Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalysed by distinct subsets of rat liver cytochrome P450. Drug Metabolism and Disposition 1996; 24: 1254–1262
   PubMed Web of Science ®Google Scholar
• Zheng JJ, Chan KK, Muggia F. Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemotherapy and Pharmacology 1994; 33: 391–479
   PubMed Web of Science ®Google Scholar